Author

A. Madrigal

h-index 3 View on Semantic Scholar

We have 3 of 14 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

45 Targeting Lysyl Oxidase Inhibits Tumor Progression in Clear Cell Renal Cell Carcinoma

Abstract Background Clear cell renal cell carcinoma (ccRCC) is defined by constitutive pseudohypoxia driven by von Hippel-Lindau (VHL) loss, pronounced intratumoral heterogeneity, and aberrant hypervascularity, features that collectively promote tumor progression and limit therapeutic durability. Although VEGF-targeted...

B. Ulukan, O. Saatci, A. Madrigal et al. · The Oncologist · 0 citations

Open access Sep 2026

TCF4 Mediates PHF6 Transcriptional Regulation of Neural Stem Cells in the Developing Brain, a Mechanism Disrupted in Börjeson–Forssman–Lehmann Syndrome (BFLS)

A PHF6-Tcf4 transcriptional pathway is established that restricts NSC self-renewal and links disrupted transcriptional control of NSC fate to the neurodevelopmental and behavioral abnormalities of BFLS.

Behnaz Nateghi, Yun-Qiao Li, Dian-Bo Qu et al. · bioRxiv · 0 citations

Open access Jul 2026

Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment

Using single-cell transcriptomics, lysyl oxidase (LOX) is identified as a driver of ccRCC progression, selectively enriched in a hypoxia/epithelial-mesenchymal transition (EMT) gene program associated with poor outcome.

B. Ulukan, O. Saatci, A. Madrigal et al. · bioRxiv · 0 citations